Note: before purchasing and taking medicines, a hospital genetic test report and a doctor's diagnosis report or certificate must be produced
Adjuvant therapy for early breast cancer: adjuvant therapy for postmenopausal women with hormone receptor positive early breast cancer.
Extended adjuvant therapy for early breast cancer: extended adjuvant therapy for early breast cancer in postmenopausal women who have received 5 years of adjuvant ta-moxifen. The effectiveness of letrozole in extending adjuvant treatment of early breast cancer is based on an analysis of disease-free survival in patients treated with letrozole for a median of 60 months.
First - and second-line treatment of advanced breast cancer: first-line treatment for postmenopausal women with hormone receptor positive or unknown, locally advanced, or metastatic breast cancer. Letrozole is also used to treat advanced breast cancer in postmenopausal women whose disease has progressed after anti estrogen therapy.
The recommended dose of letrozole is a 2.5 mg tablet administered once daily, irrespective of meals.
Letrozole can cause fetal harm and is contraindicated in pregnant and lactating women.